TARVASMAKI, T., J. LASSUS, M. VARPULA, A. SIONIS, R. SUND, L. KOBER, Jindřich ŠPINAR, J. PARISSIS, M. BANASZEWSKI, J. S. CARDOSO, V. CARUBELLI, S. DI SOMMA, A. MEBAZAA a V.P. HARJOLA. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Critical Care. LONDON: BioMed Central, 2016, roč. 20, č. 208, s. 1-11. ISSN 1466-609X. Dostupné z: https://dx.doi.org/10.1186/s13054-016-1387-1.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality
Autoři TARVASMAKI, T. (246 Finsko), J. LASSUS (246 Finsko), M. VARPULA (246 Finsko), A. SIONIS (724 Španělsko), R. SUND (246 Finsko), L. KOBER (208 Dánsko), Jindřich ŠPINAR (203 Česká republika, garant, domácí), J. PARISSIS (300 Řecko), M. BANASZEWSKI (616 Polsko), J. S. CARDOSO (620 Portugalsko), V. CARUBELLI (380 Itálie), S. DI SOMMA (380 Itálie), A. MEBAZAA (250 Francie) a V.P. HARJOLA (246 Finsko).
Vydání Critical Care, LONDON, BioMed Central, 2016, 1466-609X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 5.358
Kód RIV RIV/00216224:14110/16:00091578
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1186/s13054-016-1387-1
UT WoS 000379589600001
Klíčová slova anglicky Cardiogenic shock; Vasoactive medication; Vasopressors; Inotropes; Adrenaline; Mortality; Survival; Propensity score
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 10. 11. 2016 12:52.
Anotace
Background: Vasopressors and inotropes remain a cornerstone in stabilization of the severely impaired hemodynamics and cardiac output in cardiogenic shock (CS). The aim of this study was to analyze current real-life use of these medications, and their impact on outcome and on changes in cardiac and renal biomarkers over time in CS. Methods: The multinational CardShock study prospectively enrolled 219 patients with CS. The use of vasopressors and inotropes was analyzed in relation to the primary outcome, i.e., 90-day mortality, with propensity score methods in 216 patients with follow-up data available. Changes in cardiac and renal biomarkers over time until 96 hours from baseline were analyzed with linear mixed modeling. Results: Patients were 67 (SD 12) years old, 26 % were women, and 28 % had been resuscitated from cardiac arrest prior to inclusion. On average, systolic blood pressure was 78 (14) and mean arterial pressure 57 (11) mmHg at detection of shock. 90-day mortality was 41 %. Vasopressors and/or inotropes were administered to 94 % of patients and initiated principally within the first 24 hours. Noradrenaline and adrenaline were given to 75 % and 21 % of patients, and 30 % received several vasopressors. In multivariable logistic regression, only adrenaline (21 %) was independently associated with increased 90-day mortality (OR 5.2, 95 % CI 1.88, 14.7, p = 0.002). The result was independent of prior cardiac arrest (39 % of patients treated with adrenaline), and the association remained in propensity-score-adjusted analysis among vasopressor-treated patients (OR 3.0, 95 % CI 1.3, 7.2, p = 0.013); this was further confirmed by propensity-score-matched analysis. Adrenaline was also associated, independent of prior cardiac arrest, with marked worsening of cardiac and renal biomarkers during the first days. Dobutamine and levosimendan were the most commonly used inotropes (49 % and 24 %). There were no differences in mortality, whether noradrenaline was combined with dobutamine or levosimendan. Conclusion: Among vasopressors and inotropes, adrenaline was independently associated with 90-day mortality in CS. Moreover, adrenaline use was associated with marked worsening in cardiac and renal biomarkers. The combined use of noradrenaline with either dobutamine or levosimendan appeared prognostically similar.
VytisknoutZobrazeno: 14. 5. 2024 01:51